Eyenovia Logo 311 x 109.png
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
27 juil. 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Logo 311 x 109.png
Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations
18 juil. 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
07 juil. 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Logo 311 x 109.png
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China
06 juil. 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Logo 311 x 109.png
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
09 juin 2022 10h09 HE | Eyenovia, Inc.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
09 juin 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Logo 311 x 109.png
Eyenovia Announces Planned Chief Executive Officer Transition
07 juin 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™)...
Eyenovia Logo 311 x 109.png
Eyenovia Reports First Quarter 2022 Financial Results
12 mai 2022 16h05 HE | Eyenovia, Inc.
Mydcombi™ NDA resubmission on track for Q3 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as planned; topline data...
Eyenovia Logo 311 x 109.png
Eyenovia to Report First Quarter 2022 Results on Thursday, May 12
05 mai 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Logo 311 x 109.png
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
20 avr. 2022 08h00 HE | Eyenovia, Inc.
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...